Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway.
Ogishima J, Taguchi A, Kawata A, Kawana K, Yoshida M, Yoshimatsu Y, Sato M, Nakamura H, Kawata Y, Nishijima A, Fujimoto A, Tomio K, Adachi K, Nagamatsu T, Oda K, Kiyono T, Osuga Y, Fujii T. Ogishima J, et al. Among authors: nishijima a. BMC Cancer. 2018 Dec 3;18(1):1201. doi: 10.1186/s12885-018-4922-4. BMC Cancer. 2018. PMID: 30509235 Free PMC article.
Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma.
Makii C, Ikeda Y, Oda K, Uehara Y, Nishijima A, Koso T, Kawata Y, Kashiyama T, Miyasaka A, Sone K, Tanikawa M, Tsuruga T, Mori-Uchino M, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Kawana K, Hasegawa K, Fujiwara K, Aburatani H, Osuga Y, Fujii T. Makii C, et al. Among authors: nishijima a. Gynecol Oncol. 2019 Nov;155(2):331-339. doi: 10.1016/j.ygyno.2019.08.028. Epub 2019 Sep 5. Gynecol Oncol. 2019. PMID: 31493899
MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.
Makii C, Oda K, Ikeda Y, Sone K, Hasegawa K, Uehara Y, Nishijima A, Asada K, Koso T, Fukuda T, Inaba K, Oki S, Machino H, Kojima M, Kashiyama T, Mori-Uchino M, Arimoto T, Wada-Hiraike O, Kawana K, Yano T, Fujiwara K, Aburatani H, Osuga Y, Fujii T. Makii C, et al. Among authors: nishijima a. Oncotarget. 2016 Nov 15;7(46):75328-75338. doi: 10.18632/oncotarget.12175. Oncotarget. 2016. PMID: 27659536 Free PMC article.
Histone arginine methyltransferase CARM1 selective inhibitor TP-064 induces apoptosis in endometrial cancer.
Inoue F, Sone K, Toyohara Y, Tanimoto S, Takahashi Y, Kusakabe M, Kukita A, Honjoh H, Nishijima A, Taguchi A, Miyamoto Y, Tanikawa M, Iriyama T, Uchino MM, Tsuruga T, Wada-Hiraike O, Oda K, Osuga Y. Inoue F, et al. Among authors: nishijima a. Biochem Biophys Res Commun. 2022 Apr 23;601:123-128. doi: 10.1016/j.bbrc.2022.02.086. Epub 2022 Feb 23. Biochem Biophys Res Commun. 2022. PMID: 35245741
Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma.
Matsushita H, Hasegawa K, Oda K, Yamamoto S, Asada K, Karasaki T, Yabuno A, Nishijima A, Nejo T, Kobayashi Y, Sato S, Ikeda Y, Miyai M, Takahashi Y, Yamaguchi R, Fujiwara K, Aburatani H, Kakimi K. Matsushita H, et al. Among authors: nishijima a. J Immunother Cancer. 2020 May;8(1):e000375. doi: 10.1136/jitc-2019-000375. J Immunother Cancer. 2020. PMID: 32461346 Free PMC article.
The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma.
Matsushita H, Hasegawa K, Oda K, Yamamoto S, Nishijima A, Imai Y, Asada K, Ikeda Y, Karasaki T, Fujiwara K, Aburatani H, Kakimi K. Matsushita H, et al. Among authors: nishijima a. Oncoimmunology. 2017 Jun 16;6(8):e1338996. doi: 10.1080/2162402X.2017.1338996. eCollection 2017. Oncoimmunology. 2017. PMID: 28920005 Free PMC article.
Ultrastructure and x-ray microanalysis of siderosome.
Sato S, Ogihara Y, Nishijima A, Shinohara M. Sato S, et al. Among authors: nishijima a. Arch Dermatol Res. 1978 Apr 7;261(2):113-21. doi: 10.1007/BF00447156. Arch Dermatol Res. 1978. PMID: 207228
80 results